RESEARCH SUMMARY

Bifidobacterium longum BL21 probiotic may improve HbA1c when added to metformin in type 2 diabetes

Moderate confidence
Some Concerns bias
Last updated May 4, 2026

Key takeaway:

A 12-week double-blind RCT in adults with T2DM found that adding Bifidobacterium longum BL21 to metformin significantly lowered HbA1c by 0.3% and favorably shifted gut microbiota compared to placebo.

Study at a glance

Study type

RCTs

duration

Short-Term (≤3 mo)

Intervention

Probiotics

Outcomes

HbA1c, Fasting Plasma Glucose, Insulin resistance, Triglycerides, Gut microbiota diversity

Funding

Non-industry sponsored

What was studied

Whether adding BL21 probiotic to metformin improves glycemic control in T2DM

What they found

  • ↓ HbA1c (0.3% reduction vs placebo, p=0.026, meeting ADA MCID threshold)
  • ↑ Beneficial gut bacteria (Bifidobacterium, Faecalibacterium enriched)
  • → Fasting glucose, insulin resistance, triglycerides showed non-significant improvement trends

mainEffects

↓ HbA1c (0.3% reduction vs placebo, p=0.026, meeting ADA MCID threshold)

↑ Beneficial gut bacteria (Bifidobacterium, Faecalibacterium enriched)

→ Fasting glucose, insulin resistance, triglycerides showed non-significant improvement trends

Evidence Suggest

  • BL21 significantly reduced HbA1c compared to placebo as an adjunct to metformin (p=0.026)
  • Favorable gut microbiota changes with increased SCFA-producing genera and reduced pathogenic taxa
  • Safety profile comparable to placebo with no serious adverse events reported

Who this applies to

Adults with type 2 diabetes currently taking metformin who have room for improvement in their blood sugar control and are interested in evidence-based probiotic options as a supportive therapy.

Keep in Mind

The HbA1c reduction of 0.3% is modest compared to prescription diabetes medications. The non-significant findings for fasting glucose and insulin resistance suggest not all metabolic parameters benefited. The study was also relatively small and short, so larger and longer trials are needed to confirm whether this effect lasts and who benefits most.

Between the Lines

  • Small sample size without formal a priori power calculation
  • 12-week duration may not capture long-term efficacy or sustainability
  • Gut microbiota analysis was taxonomic/descriptive without direct SCFA measurement

Unlock Full Analysis

Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.

Already have an account?

Sources

guidelines

American Diabetes Association Standards of Care in Diabetes—2025: Pharmacologic Approaches to Glycemic Treatment

The ADA's clinical practice guidelines establish the minimum clinically important difference (MCID) threshold for HbA1c reduction (0.3%–0.5%) and provide evidence-based recommendations for adjunctive therapies in type 2 diabetes management.
guidelines

Insulin Resistance & Type 1 | ADA

Insulin resistance is a problem found in people with prediabetes and type 2 diabetes, but people with type 1 diabetes can become insulin resistant, too.
guidelines

Standards of Care in Diabetes—2024

Annual ADA clinical practice guideline issue covering broad diabetes management.
guidelines

Type 2 diabetes in adults: management

NICE clinical guideline for adult type 2 diabetes management.
guidelines

A Guide for People with Type 2 Diabetes | American Diabetes Association

American Diabetes Association resource matched by keyword relevance (type 2 diabetes)
guidelines

Diabetes Diagnosis & Tests | ADA

Learn about the diabetes diagnosis criteria and various tests used like A1C, Fasting Plasma Glucose (FPG), Oral Glucose Tolerance Test (OGTT), and Random Plasma Glucose Test.
healthAuthorities

International Diabetes Federation - IDF Diabetes Atlas 10th Edition

The IDF Diabetes Atlas provides the global prevalence data cited in the study (537 million adults with diabetes in 2021, projected to reach 783 million by 2045), establishing the public health context for T2DM research.
healthAuthorities

NIH National Center for Complementary and Integrative Health - Probiotics: What You Need To Know

The NCCIH provides evidence-based information about probiotics, including strain-specific effects, regulatory considerations, and current evidence for probiotic use in various health conditions including metabolic disorders.
studiesGroup

Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis.

2026
studiesGroup

Beyond insulin therapy: Comparing relative benefits of adding SGLT2 versus DPP4 inhibitors in poorly controlled type 2 diabetic patients: A systematic review and meta-analysis.

2026
studiesGroup

The role of peripheral blood HIF-1α in pancreatic β-cell dysfunction and insulin resistance among patients with type 2 diabetes: a systematic review and meta-analysis.

2026
studiesGroup

Association between triglyceride-glucose (TyG) index and diabetic foot ulcers in adult inpatients with type 2 diabetes at hospital admission.

2026
studiesGroup

Association between triglyceride-glucose index and diabetic retinopathy among patients with diabetes mellitus in Nepalese patients: a cross-sectional study.

2026

No ads. No tracking

A clean, privacy-first research experience.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.